

TABLE 3 MAJOR COVID-19 AND CANCER REGISTRIES*

Name	Cancer Type	Eligibility Criteria	Region(s) Covered
COVID-19 and Cancer Consortium (CCC19)	Blood cancers and solid tumors	Patients age >18 years with suspected or laboratory-confirmed COVID-19	North America, European Union, United Kingdom, and Argentina
OnCovid	Blood cancers and solid tumors	Patients age ≥18 years with confirmed COVID-19	United Kingdom, Spain, Italy, Germany
UK Coronavirus Cancer Monitoring Project (UK CCMP)	Blood cancers and solid tumors	Confirmed COVID-19	United Kingdom
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT)	Thoracic cancers	Confirmed COVID-19	34 countries from five continents
American Society of Clinical Oncology Survey on COVID-19 in Oncology Registry	Blood cancers and solid tumors	Patients with COVID-19 with active cancer or cancer-free for less than 12 months and receiving adjuvant therapy at the time of COVID-19 diagnosis	United States
American Society of Hematology Research Collaborative (ASH RC)	Blood cancers	Confirmed COVID-19 and hematologic condition (cancer and noncancer)	United States
European Society for Medical Oncology COVID-19 Care (ESMO-CoCARE)	Blood cancers and solid tumors	Confirmed COVID-19	Europe, Africa, and Asia
NCI COVID-19 in Cancer Patients Study (NCCAPS)	Blood cancers and solid tumors	Patients from all age groups who received a positive test result for SARS-CoV-2	United States
Global Registry of COVID-19 in Childhood Cancer	Blood cancers and solid tumors	Patients less than one year old to 18 years old with cancer and COVID-19	51 countries from four continents
The Leukemia and Lymphoma Society National Patient Registry	Blood cancers	Patients with blood cancer with or without COVID-19	United States

*Only selected registries with 1,000 or more patients accrued are included in the table.